Lead Sponsor

Actelion

Age

12 - No limit years

Sex

ALL

Healthy Volunteers

No

•Signed informed consent prior to initiation of any study-mandated procedure.
•Patients with pulmonary arterial hypertension and having completed the event-driven study, AC 055 302/SERAPHIN, or Patients who have experienced a clinical worsening of PAH in AC 055 302/SERAPHIN and for whom a written approval to roll over into this study has been obtained from the Sponsor.
•Women of childbearing potential must have a negative pre-treatment serum pregnancy test and must use a reliable method of contraception during study treatment and for at least 28 days after study treatment termination.

•Any major violation of protocol AC 055 302/SERAPHIN.
•Pregnancy or breast-feeding.
•AST and/or ALT \> 3 times the upper limit of the normal range.
•Any known factor or disease that might interfere with treatment compliance, study conduct or interpretation of the results, such as drug or alcohol dependence or psychiatric disease.
•Known hypersensitivity to ACT 064992 or any of the excipients.

Related studies

NCT07218029 · Pulmonary Arterial Hypertension

NCT07365332 · Pulmonary Arterial Hypertension

NCT06649110 · Healthy Volunteers, Pulmonary Arterial Hypertension

NCT07120789 · Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), and more

NCT07457762 · Pulmonary Arterial Hypertension (PAH)

Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension